Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England.

Abstract excerpt

OBJECTIVES: Real-world analyses of first-line maintenance (1LM) immuno-oncology (IO) treatment with or without pemetrexed for patients with non-squamous (NSQ) advanced/metastatic non-small cell cancer (a/mNSCLC), including the relative impact of 1LM pemetrexed, are lacking. This retrospective analysis describes 1LM treatment patterns and their outcomes in England. METHODS: Data from the National Disease...

Topics

Join the communities discussing this publication.

• Antineoplastic Combined Chemotherapy Protocols
• Carcinoma, Non-Small-Cell Lung
• COVID-19
• England